Breast cancer (BC) has a high mortality rate and metastatic BC is almost incurable despite hormonal therapy and chemotherapy. The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months. Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have been extensively investigated in this setting. The presence of immune mediated anti-tumor effects referred to as graft-versus-tumor (GvT) effects after allogeneic HSCT among patients with solid tumors have been clearly defined. The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen compatible donor T-cells. In conclusion, a GvT effect does exist against metastatic BC and play a key role in tumor response. This review aims to describe the background, rationale, and clinical results of allogeneic HSCT as a potential alternative treatment in metastatic BC.
INTRODUCTION
Breast cancer (BC) is the most common cancer among women and the second most common cause of cancer death in women, accounting for 40.000 deaths annually in the United States 1 . Metastatic BC is almost incurable despite hormonal therapy and chemotherapy 2, 3 . The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months 4 . Due to this limited efficacy of chemotherapy, the development of novel therapeutic strategies to currently available modalities has become essential. Higher dose -better response concept has been accepted as a treatment strategy in 1980s and highdose chemotherapy (HDC) has been used for metastatic BC since then [5] [6] [7] [8] [9] . However, increasing the chemotherapy dose in advanced BC has not been reported to be beneficial, neither on overall survival (OS) 10-12 nor relapse-free survival (RFS) 13 . Regimens employing autologous hematopoietic stem cell transplantation (HSCT) following HDC have been developed in order to avoid myelotoxic effects of HDC [14] [15] [16] [17] [18] [19] [20] . Although this approach is expected to increase survival by optimizing tumor response [21] [22] [23] [24] [25] , its efficacy is controversial. A meta-analysis of 15 well-known randomized trials of HDC plus autologous HSCT for high-risk primary BC reported a benefit in RFS, but not OS as well as metastatic BC had been published [49] [50] [51] [52] . This review aims to describe the background, rationale and clinical results of allogeneic HSCT as an alternative treatment in metastatic BC.
Graft-versus-tumor effect in breast cancer
Graft versus leukemia effect was first demonstrated in a leukemiac murine model that received allogeneic HSCT from other strains of mice following high-dose body irradiation 53 . Later, GvT effect in a solid tumor after allogeneic BMT has also been demonstrated in a murine model in 1984 54 .Morecki et al. demonstrated a GvT effect in mice implanted with 4T1 mammary carcinoma cell line and given minor histocompatibility mismatched DBA/2 spleen cells 55 . This direct GvT effect mediated by the alloreactive donor splenocytes in the absence of any anti-carcinoma agents has also been demonstrated by direct inhibition of liver metastases through intraportal inoculation of allogeneic splenocytes, but not syngeneic splenocytes 56 . The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen(HLA)-compatible donor Tcells 33, 36 . These immune-mediated effects led to a transition from a chemotherapy-based approach to an immunotherapy-based approach in the management of BC 57 .The switch from targeting maximal tumor cytoreduction via HDC to induction of immune GVT effects also gave rise to development of RIC and NMA regimens instead of conventional myeloablative conditioning regimens 41, 49 . RIC regimens substantially reduced the high transplant-related morbidity and mortality [37] [38] [39] [40] 58 while allowing for a complete myeloid/lymphoid engraftment [45] [46] [47] [50] [51] [52] . As a result, allogeneic HSCT .
RESULTS
After demonstration of tumor regression in metastatic BC via allogeneic T-lymphocyte mediated GvT effects in several murine models 59, 60 , the National Cancer Institute of the National Institutes of Health in the USA investigated whether a clinical graft-versus-BC effect existed via allogeneic lymphocytes after allogeneic HSCT from HLAmatched siblings following a RIC regimen 61 . The study included 16 metastatic BC patients who had progressed after chemotherapy and hormonal therapy. In order to avoid the overlap of immunological GvT effect and anti-tumor effect of cytotoxic chemotherapy used in the pre-transplant conditioning regimen, allogeneic T-lymphocytes were removed from the stem cell graft and were subsequently administered at escalating doses after allogeneic HSCT (on +42, +70, and +98 days). Objective tumor regression occurred in six patients 28 days after allogeneic HSCT. Disease progression following allogeneic HSCT was observed before subsequent tumor regression in 2 of the 6 patients. Tumor regressions obtained simultaneously with the accomplishment of complete donor T-lymphoid engraftment associated with the development of graft-versus-host disease (GvHD) and abrogated after systemic immunosuppression 52 . Another study evaluated HDC plus autologous HSCT combined with allogeneic HSCT following RIC regimen 62 . With this strategy, Carella, et al. aimed to achieve maximum tumor reduction prior to allogeneic HSCT. This approach may provide the benefits of a conventional allograft while reducing the typical acute toxicities and myeloablative therapy associated mortality. The study enrolled 17 metastatic BC patients with a median age of 41 years. The primary endpoint of the study was to decrease the non-relapse mortality (NRM), which is currently reported as 20-35% following allografting with NMA. Donor engraftment was established in 13 patients. Partial remission after HDC plus autologous HSCT was present in 3 patients who achieved complete remission after the development of GvHD following allogeneic HSCT with RIC. Grade II or higher acute GvHD was observed in 5 patients (29%) and chronic GvHD requiring systemic immunosuppression in 6 patients (5 had extensive involvement). No NRM-related death occurred in the first 100 days after allogeneic HSCT. At a median of 1320 days (range 90-2160) after allogeneic HSCT, 5 patients (29%) were alive (3 achieved complete remission and 2 had stable disease). Ueno 
. MAC and RIC regimen was given to 39 (59%) and 27 (41%) patients, respectively. Despite including a significantly higher number of patients with poor prognostic features before the transplant (63% vs. 26%, p<0.002), treatment-related mortality was lower in the RIC group (7% vs 29% at 100 days, p< 0.03). RFS at 1 year was higher in the MAC group, but it did not reach statistical significance (23% vs 8%, p<0.09). Consistent with a GvT effect, patients who developed acute GvHD following RIC regimen had lower relapse or progression risk than those who did not (p<0.03); however, this did not translate into a RFS advantage [33] . Immune manipulation such as donor lymphocyte infusion (DLI) for persistent or progressive disease was performed in 9 out of 33 patients (27%) and led to disease response or stable disease. Authors concluded that preclinical and clinical studies are needed in order to facilitate targeted adoptive immunotherapy to explore the benefit of a GvT effect in breast cancer 33 . Despite its great potential, ATCT for cancer control still has a marginal role in the management of patients with solid tumors although its use in the setting of melanoma seems ready for development as a routine therapy 63 . Indeed, the extensive infrastructure needed for exploiting ATCT still restricts its use to academic centers with specific programs in the field. We have to emphasize that the major obstacle for a wider application of ATCT to treat human cancer is the personalized nature of the approach 63 . More clinical studies will result in deployment of innovative allogeneic HSCT 
